ARTICLE | Clinical News
Drisapersen regulatory update
July 13, 2015 7:00 AM UTC
FDA and EMA accepted for review applications from BioMarin for drisapersen to treat Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The NDA is under Priority Review, with a Dec. 27 PDU...